Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9394290
APP PUB NO 20140155407A1
SERIAL NO

13880701

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITAET DES SAARLANDESCAMPUS SAARBRUECKEN 66123

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hartmann, Rolf Saarbruecken, DE 34 365
Hille, Ulrike Loerrach, DE 1 6
Hu, Qingzhong Saarbruecken, DE 4 7
Vock, Carsten A Friedland, DE 1 6
Zimmer, Christina Voelklingen, DE 4 8

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 19, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00